Advanced Enzyme FY26 Results: ₹7,458m revenue, ₹1,736m PAT

Board clears audited FY26 numbers

Advanced Enzyme Technologies said its Board of Directors approved the audited standalone and consolidated financial results for the year ended March 31, 2026, along with fourth quarter results. The approval came at a board meeting held on May 09, 2026. The company reported higher revenue from operations and higher net profit compared with the previous year on both consolidated and standalone bases. The statutory auditors, M S K A & Associates LLP, issued an unmodified audit opinion on the FY26 standalone and consolidated financial results.

Consolidated FY26 performance: revenue and profit rise

On a consolidated basis, revenue from operations increased to ₹7,457.57 million in FY26 from ₹6,369.10 million in FY25. Net profit for the year rose to ₹1,736.08 million from ₹1,339.74 million. The company also reported total comprehensive income of ₹2,684.19 million compared with ₹1,527.96 million in the previous year. Separately, the disclosure also cited year-on-year growth rates of 17% for consolidated revenue and 29.6% for consolidated net profit.

Standalone FY26 performance

On a standalone basis, revenue from operations increased to ₹4,527.66 million in FY26 from ₹3,514.11 million in FY25. Standalone net profit rose to ₹1,318.06 million from ₹1,024.20 million. The company’s standalone growth rates were also stated as 28.8% for revenue and 28.7% for net profit.

Q4 detail disclosed in the release

Alongside full-year numbers, the disclosure referenced a sharp rise in quarterly profitability. Q4 FY26 net profit was stated at ₹453 million, up 69% year-on-year. The company did not provide additional quarterly line items in the text shared, beyond this profit figure.

Dividend: ₹1.35 per share recommended, interim deferred

The board recommended a final dividend of ₹1.35 per equity share for FY26, subject to shareholder approval at the ensuing 37th Annual General Meeting (AGM). The company specified this as 67.5% on the face value of ₹2 per share.

The board also decided to defer declaring an interim dividend. It cited the need to preserve capital flexibility while evaluating potential strategic avenues and corporate actions aimed at long-term shareholder value.

Directors and auditors: reappointments and new independent director

The board approved the re-appointment of Mukund Madhusudan Kabra (DIN: 00148294) as Whole Time Director for a further five-year term from April 01, 2027 to March 31, 2032, subject to shareholder approval at the 37th AGM. It also appointed Pradip Bhailal Shah (DIN: 01225582) as an Additional Director (Independent), effective June 12, 2026. The proposed tenure is five years from June 12, 2026 to June 11, 2031, subject to member approval.

The board approved the reappointment of M S K A & Associates LLP (FRN: 105047W/W101187) as statutory auditors for a second term of five consecutive years, from the conclusion of the 37th AGM to the conclusion of the 42nd AGM.

ESOP allotment and change in share capital

The board approved allotment of 49,350 equity shares of face value ₹2 per share under the Advanced Enzyme Technologies Limited Employees Stock Options Scheme 2022. Following the allotment, paid-up share capital increased from ₹223.8536 million (11,19,26,800 equity shares of ₹2 each) to ₹223.9523 million (11,19,76,150 equity shares of ₹2 each). The change reflects the addition of 49,350 shares.

Conference call: date, time, dial-in and contact

Advanced Enzyme Technologies announced a conference call for analysts and investors to discuss results for the quarter and year ended March 31, 2026. The company said the disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to stock exchanges on May 05, 2026 by Company Secretary and Head of Legal, Sanjay Basantani.

The call is scheduled for Tuesday, May 12, 2026 at 09:00 hours IST. Primary dial-in numbers shared were +91 86 3416 8438 and +91 86 4536 6489, with participant PIN (international) 4773312#. For investor relations, the company listed Ronak Saraf (Investor Relations) at ir@advancedenzymes.com and +91 86578 64146.

Market snapshot and dividend context in the disclosure

The text included a market snapshot with a price of 298.45 and a change of 4.10 (1.39%), with an intraday range of 291.00 to 301.50. It also included dividend yield figures of 1.46 and 1.94, as presented.

The disclosure also provided historical dividend entries, including FY25 dividends: a final dividend of ₹1.20 per share (60%) and an interim dividend of ₹4.00 per share (200%). It further mentioned an interim dividend declared during FY26 at ₹4.00 per share (200%), aggregating to about ₹447.52 million, and an FY25 interim dividend aggregating to about ₹447.30 million, along with FY25 final dividend aggregation of about ₹134.26 million.

Key figures at a glance

Timeline and corporate actions

Why the FY26 announcement matters

The FY26 results show year-on-year improvement in both revenue and net profit on consolidated and standalone bases, based on audited numbers approved by the board. The dividend decision is notable because the company proposed a final dividend of ₹1.35 per share but deferred an interim dividend, explicitly linking the decision to capital flexibility for strategic evaluation. The ESOP allotment increased the share count and paid-up capital, a relevant datapoint for shareholders tracking equity changes.

What to watch next

Shareholders will vote on the final dividend recommendation and the board and auditor-related resolutions at the upcoming 37th AGM. Investors also have a near-term date on the calendar with the May 12, 2026 conference call scheduled to discuss the quarter and full-year performance.